In this issue:
Ribociclib promising in advanced HR+/HER2– disease
Locoregional therapy and survival outcomes in TNBC
The current state of immunotherapy in breast cancer
The science of endocrine resistance
Avoiding ONJ and hypocalcaemia with bone-targeted agents
Replacing tissue biopsies with liquid biopsy
Therapeutic options after failure of pertuzumab and TDM1
Offer neratinib as SOC in HER2+ disease?
Should all TNBC receive a platinum agent?
Please login below to download this issue (PDF)